Leukemia, B-cell Clinical Trials

25 clinical trials for Leukemia, B-cell across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies — RECRUITING
• A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) — RECRUITING · PHASE3
• Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL) — RECRUITING · PHASE1
• Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation — COMPLETED · PHASE1
• A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY) — NOT_YET_RECRUITING · PHASE1
• Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. — ACTIVE_NOT_RECRUITING · PHASE4
• INS19 CAR-T Cells for the Treatment of Relapsed or Refractory Acute B Lymphoblastic Leukemia — OTHER · PHASE1
• Precision Exercise in Children With Malignant Hemopathies — OTHER · NA
• CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia. — OTHER · PHASE1
• Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma — OTHER · PHASE1
• CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma — OTHER · PHASE1
• Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma — OTHER · PHASE1
• CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma — OTHER · PHASE1
• CAR-T Cells in the Treatment of Malignant Hematological Tumors — OTHER · NA
• Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL — OTHER · PHASE2
• Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma — WITHDRAWN · PHASE1
• γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse — OTHER · PHASE1
• XLCART001 Treatment in Relapsed/Refractory/High-risk B-cell Malignancy Subjects — OTHER · PHASE2
• Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL — TERMINATED · PHASE1
• Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma — TERMINATED · PHASE2
• Immunotherapy With CD19 CART-cells for B Cell Acute Lymphoblastic Leukemia — OTHER · PHASE1
• CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation — OTHER · NA
• Chimeric Antigen Receptor T Cells (CART) Therapy in Refractory/Relapsed B Cell Hematologic Malignancies — OTHER · NA
• A Study to Assess CD19-targeted Immunotherapy T Cells in Patients With Relapsed or Refractory CD19+ B Cell Leukemia — OTHER · PHASE1

Refine this search